Cetera Investment Advisers Has $59.17 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Cetera Investment Advisers raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 15.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,335,151 shares of the biopharmaceutical company's stock after buying an additional 313,587 shares during the quarter. Cetera Investment Advisers' holdings in Pfizer were worth $59,173,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Avantax Advisory Services Inc. grew its holdings in Pfizer by 5.9% in the 1st quarter. Avantax Advisory Services Inc. now owns 369,411 shares of the biopharmaceutical company's stock valued at $9,361,000 after buying an additional 20,421 shares in the last quarter. Hamilton Point Investment Advisors LLC grew its holdings in Pfizer by 18.5% in the 1st quarter. Hamilton Point Investment Advisors LLC now owns 175,596 shares of the biopharmaceutical company's stock valued at $4,450,000 after buying an additional 27,431 shares in the last quarter. Brookwood Investment Group LLC acquired a new position in Pfizer in the 1st quarter valued at $227,000. Jackson Hole Capital Partners LLC grew its holdings in Pfizer by 11.9% in the 1st quarter. Jackson Hole Capital Partners LLC now owns 110,837 shares of the biopharmaceutical company's stock valued at $2,809,000 after buying an additional 11,828 shares in the last quarter. Finally, Lincluden Management Ltd. grew its holdings in Pfizer by 7.7% in the 1st quarter. Lincluden Management Ltd. now owns 415,454 shares of the biopharmaceutical company's stock valued at $10,528,000 after buying an additional 29,617 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $24.79 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $140.91 billion, a PE ratio of 17.96, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a 50-day moving average price of $24.30 and a two-hundred day moving average price of $24.68.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% on a year-over-year basis. During the same period last year, the company earned $0.82 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.94%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Wolfe Research increased their target price on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Redburn Atlantic reduced their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. TD Cowen reduced their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.